Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Repligen Corporation
Acquired Company
BioLife Solutions
WalthamBothellManufacturingBiotechnologyHealthcareBiopharmaBiotechnologyDescription
Repligen has finalized its acquisition of BioLife Solutions, enhancing its presence in the cell therapy market. The deal, valued at approximately $1.5 billion, aims to leverage BioLife's established products and customer relationships. Repligen expects significant synergies in the first year post-acquisition. Both companies plan a thoughtful integration to maximize the combined capabilities in the growing therapeutic landscape.
Fundz sees it the moment Repligen Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired BioLife Solutions?
BioLife Solutions was acquired by Repligen Corporation, based in Waltham. The deal was reported on October 6, 2026. Repligen Corporation is publicly traded (RGEN) and operates in Manufacturing.
When did Repligen Corporation acquire BioLife Solutions?
Repligen Corporation's acquisition of BioLife Solutions was reported on October 6, 2026. Repligen has finalized its acquisition of BioLife Solutions, enhancing its presence in the cell therapy market. The deal, valued at approximately $1.5 billion, aims to leverage BioLife's established products and customer relationships. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does BioLife Solutions do?
BioLife Solutions, Inc. is a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. It is publicly traded (BLFS), operating in Biotechnology, and is based in Bothell.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.